Country
Clinical Trials in Sri Lanka
Studies with at least one site in Sri Lanka. Open a trial for its sites in Sri Lanka, who to contact and who can take part.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 20Heart Failure With Reduced Ejection Fraction
HFrEF Polypill in Sri Lanka RCT
The aim of this study is to evaluate, in adults with HFrEF in Sri Lanka, the effects of an HFrEF polypill implementation strategy on the composite rate of cardiovascular disease mortality and recurrent heart failure…
- Trial name
- NCT07569640
- Testing
- Usual Care, HFrEF Polypill
- Where
- 12 sites in Sri Lanka
- Volunteers
- 1,672 people
- Sponsor
- Washington University School of Medicine
Chronic Lung Diseases
Prospective Study on Antimicrobial RESIstance in Chronic Pulmonary DiseasE
This observational, multicentric prospective study aims to understand the prevalence and burden of antimicrobial resistance (AMR) in people with chronic lung diseases (CLD) across the globe, understanding also geographical…
- Trial name
- PRESIDE (NCT07874139)
- Where
- 68 sites in United States, Albania and 31 more
- Volunteers
- 683 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Skin Ageing, Skin
Skin Type Determination Using Image Artificial Intelligence
Skin color, how easily a person burns or tans in the sun (skin phototype), and the amount of chronic sun damage in the skin are important factors in skin health.
- Trial name
- SPAI (NCT07765303)
- Testing
- Skin imaging and skin characteristic assessment
- Where
- 13 sites in Australia, Brazil and 9 more
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Region Skane
Chronic Kidney Diseases
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).
- Trial name
- CAPTIVATE (NCT06058585)
- Testing
- Finerenone, Semaglutide
- Where
- 51 sites in Australia, India and 3 more
- Volunteers
- 2,000 people
- Sponsor
- The George Institute
Heart Failure, Acute Heart Failure
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
- Trial name
- REDEFINE-HF (NCT06008197)
- Testing
- Finerenone
- Where
- 356 sites in United States, Argentina and 24 more
- Volunteers
- 5,200 people
- Sponsor
- Colorado Prevention Center
Heart Failure
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
- Trial name
- CONFIRMATION (NCT06024746)
- Testing
- Finerenone, Empagliflozin
- Where
- 140 sites in United States, Brazil and 6 more
- Volunteers
- 1,500 people
- Sponsor
- Colorado Prevention Center
Pesticide Poisoning
Administering Atropine Through Autoinjectors Within Ambulance Services for Poisoning Patients in Sri Lanka's North Central Province
Pesticide poisoning remains one of the most serious public health challenges in rural Sri Lanka, particularly in the North Central Province (NCP), where intensive farming and heavy pesticide use have led to high rates of…
- Trial name
- FAST-AID (NCT07581301)
- Testing
- Pre-hospital Atropine Autoinjector Administration
- Where
- Sri Lanka
- Volunteers
- 30 people
- Sponsor
- University of Edinburgh
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis
Study of WAL0921 in Patients With Glomerular Kidney Diseases
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and…
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
- Trial name
- NCT06466135
- Testing
- WAL0921
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 96 people
- Sponsor
- Walden Biosciences
Lower Resp Tract Infection
TREATment of Lower Respiratory Tract Infection in Selected Hospitals in Southern Sri Lanka (TREAT-SL): a Stepped-Wedge Cluster Randomized Trial
This is a stepped-wedge, cluster-randomized, two-arm, open-label, clinical trial of an electronic clinical decision support tool (eCDST) for the diagnosis and treatment of lower respiratory tract infection (LRTI) among patients…
- Trial name
- TREAT-SL (NCT06331364)
- Testing
- electronic clinical decision support tool (eCDST) diagnostic plan
- Where
- 3 sites in Sri Lanka
- Volunteers
- 765 people
- Sponsor
- Duke University
Heart Failure
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal…
- Trial name
- FINALITY-HF (NCT06033950)
- Testing
- Finerenone
- Where
- 176 sites in United States, Argentina and 12 more
- Volunteers
- 2,600 people
- Sponsor
- Colorado Prevention Center
Completed, with results posted
All –Immunoglobulin A Nephropathy, Glomerular Disease
Safety and Efficacy Study of VIS649 for IgA Nephropathy
The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
- Conditions
- Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
- Trial name
- NCT04287985
- Testing
- Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
- Where
- 93 sites in United States, Australia and 13 more
- Volunteers
- 155 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy Volunteers
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
The main purpose of this study is to evaluate the efficacy of 2 doses of Tetravalent Dengue Vaccine Candidate (TDV) in preventing symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in 4 to…
- Trial name
- TIDES (NCT02747927)
- Testing
- Tetravalent Dengue Vaccine (TDV)
- Where
- 28 sites in Brazil, Colombia and 6 more
- Volunteers
- 20,099 people, healthy volunteers welcome
- Sponsor
- Takeda
Hypertension
Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension
Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure…
- Trial name
- GMRx2_ACT (NCT04518293)
- Testing
- Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg
- Where
- 89 sites in United States, Australia and 5 more
- Volunteers
- 1,385 people
- Sponsor
- George Medicines PTY Limited
Hypertension
Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension
Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure…
- Trial name
- GMRx2_PCT (NCT04518306)
- Testing
- Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
- Where
- 47 sites in United States, Australia and 3 more
- Volunteers
- 755 people
- Sponsor
- George Medicines PTY Limited
Crohn's Disease
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naive…
- Trial name
- DIVERSITY1 (NCT02914561)
- Testing
- Filgotinib
- Where
- 513 sites in United States, Argentina and 39 more
- Volunteers
- 1,372 people
- Sponsor
- Lakefront Biotherapeutics NV